Thank you, Dr Du, for the commentary
1
regarding our article, “The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors
and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic
Review and Meta-analysis.”
2
The differential effectiveness of the 2 classes regarding the aforementioned critical
end points was highlighted in the review’s results and discussion sections. In addition,
distinctions were made on a clinical basis in the guideline (published in parallel)
and specifically concerning the absence of dedicated trials for GLP-1RAs in patients
with heart failure or chronic kidney disease. We do emphasise, with prominence, the
issue of stroke reduction with GLP-1RAs as well.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Canadian Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Obvious differences between GLP1RAs and SGLT2is in the outcomes of heart failure, renal failure, and stroke.Can J Cardiol. 2023; 39: 90
- The effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists on cardiorenal outcomes: systematic review and meta-analysis.Can J Cardiol. 2022; 38: 1201-1210
Article info
Publication history
Published online: September 21, 2022
Accepted:
September 16,
2022
Received:
September 15,
2022
Identification
Copyright
© 2022 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Obvious Differences Between GLP1RAs and SGLT2is in the Outcomes of Heart Failure, Renal Failure, and StrokeCanadian Journal of CardiologyVol. 39Issue 1
- PreviewAli et al.1 conducted a wonderful and comprehensive meta-analysis1 based on all the available cardiovascular outcome trials (CVOTs) of sodium-glucose cotransporter 2 inhibitors (SGLT2is; 11 CVOTs) and glucagon-like peptide 1 receptor agonists (GLP1RAs; 8 CVOTs), drawing their main conclusion that both SGLT2is and GLP1RAs yielded the statistically significant benefits across most cardiorenal end points in the populations studied. This conclusion only emphasises the similarity between GLP1RAs and SGLT2is in cardiorenal benefits, but ignores the differences between them in specific cardiorenal outcomes.
- Full-Text
- Preview
- The Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists on Cardiorenal Outcomes: Systematic Review and Meta-analysisCanadian Journal of CardiologyVol. 38Issue 8
- PreviewEvidence for the cardiorenal risk reduction properties of antihyperglycemic medications originally prescribed for type 2 diabetes, sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) is rapidly emerging. We completed a meta-analysis of recent literature to provide evidence-based estimates of benefit across various populations and outcomes.
- Full-Text
- Preview
